HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
esorubicin
RN given refers to parent cpd; synthesized deriv of doxorubicin
Also Known As:
4'-deoxyadriamycin; 4'-deoxydoxorubicin; 4'-deoxydoxorubicin hydrochloride; 4-desoxydoxorubicin
Networked:
71
relevant articles (
1
outcomes,
38
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
esorubicin: 71
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
esorubicin: 71
Carbohydrates: 22023
Glycosides: 2119
Aminoglycosides: 5131
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
esorubicin: 71
Related Diseases
1.
Lymphoma (Lymphomas)
07/01/1991 - "
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.
"
01/01/1987 - "
In an ADR-resistant murine L5178Y lymphoma subline sensitivity was improved with ADR and 1 microM VPM, whereas the cytotoxic effects of mitoxantrone or esorubicin were not affected by VPM.
"
01/01/1987 - "
4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors: first evidence of activity.
"
2.
Neoplasms (Cancer)
09/01/1984 - "
A phase I study of 4'deoxydoxorubicin (esorubicin) was performed on an every-21-day bolus intravenous (IV) schedule in 36 patients with advanced cancer.
"
05/01/1990 - "
Esorubicin (4'-deoxydoxorubicin, DxDx) has undergone extensive Phase II investigation for the treatment of cancer.
"
07/01/1989 - "
4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity.
"
01/01/1987 - "
A retrospective analysis was performed on the medical charts of 160 cancer patients who received esorubicin (ESO or 4'deoxydoxorubicin) in a Phase I clinical trial.
"
05/01/1985 - "
The combined treatment of the colon 26 tumor with a cytotoxic drug, 4'-deoxydoxorubicin, and MPA, which administered alone stimulated tumor growth and increased life span, caused a slight increase in the life span compared to single agents alone.
"
3.
Carcinoma (Carcinomatosis)
04/01/1992 - "
Patients with a pathologically confirmed diagnosis of metastatic or advanced epithelial-type ovarian carcinoma were entered into a Phase II trial of esorubicin.
"
11/01/1989 - "
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
"
07/01/1987 - "
Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group.
"
04/01/1987 - "
Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study.
"
01/01/1987 - "
Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
"
4.
Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/1988 - "
4'-Deoxydoxorubicin had little activity in non-small-cell lung cancer at the dose used in this study.
"
09/01/1987 - "
Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
"
07/01/1987 - "
Phase II trial of esorubicin in patients with advanced non-small cell lung cancer.
"
11/01/1985 - "
Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
"
05/01/1990 - "
One hundred thirty-six patients with histologically or cytologically documented non-small cell lung cancer or advanced breast cancer were enrolled in two concurrent CALGB clinical trials using esorubicin at a dose of 30 mg/m2 administered intravenously every 21 days.
"
5.
Breast Neoplasms (Breast Cancer)
06/01/1990 - "
Forty-six eligible women with advanced metastatic breast cancer were entered on a Phase II trial utilizing esorubicin (4'-deoxydoxorubicin) given in a dosage of 30 mg/m2 intravenously every 3 weeks.
"
11/01/1985 - "
Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer.
"
06/01/1990 - "
Esorubicin is an active agent in metastatic breast cancer; its role in treatment remains undefined.
"
06/01/1990 - "
Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer.
"
01/01/1986 - "
Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin.
"
Related Drugs and Biologics
1.
Mitoxantrone (Novantrone)
2.
esorubicin
3.
Doxorubicin (Adriamycin)
4.
Anthracyclines
5.
Antineoplastic Agents (Antineoplastics)
6.
Idarubicin (4 Demethoxydaunorubicin)
7.
Hormones (Hormone)
8.
4'-O-methyldoxorubicin
9.
acivicin (AT 125)
10.
Epirubicin (Ellence)
Related Therapies and Procedures
1.
Drug Therapy (Chemotherapy)
2.
Therapeutics